| Title |
Role of TIM-3 in ovarian cancer
|
|---|---|
| Published in |
Clinical and Translational Oncology, March 2017
|
| DOI | 10.1007/s12094-017-1656-8 |
| Pubmed ID | |
| Authors |
Y. Xu, H. Zhang, Y. Huang, X. Rui, F. Zheng |
| Abstract |
Evidences have suggested that immunotherapy for ovarian cancer is effective. Immune checkpoints have emerged in the field of cancer immunotherapy. Multiple studies have shown negative regulation of TIM-3 expression on CD4(+) and CD8(+) T cells and other immunocytes. Overexpression of TIM-3 in innate immune cells has been found in certain types of tumor. The blockade of TIM-3 leads to sustained anti-tumor reactions. TIM-3 plays an inhibitive role for immunity in ovarian cancer. TIM-3 is involved in the development of various subtypes of ovarian cancer and thus has the potential to be a therapeutic target for treatment of ovarian cancer. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 26 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 8 | 31% |
| Student > Bachelor | 5 | 19% |
| Professor | 2 | 8% |
| Student > Master | 2 | 8% |
| Student > Ph. D. Student | 1 | 4% |
| Other | 2 | 8% |
| Unknown | 6 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 5 | 19% |
| Medicine and Dentistry | 4 | 15% |
| Biochemistry, Genetics and Molecular Biology | 3 | 12% |
| Immunology and Microbiology | 2 | 8% |
| Psychology | 2 | 8% |
| Other | 1 | 4% |
| Unknown | 9 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 September 2017.
All research outputs
#20,446,373
of 23,001,641 outputs
Outputs from Clinical and Translational Oncology
#1,022
of 1,318 outputs
Outputs of similar age
#269,199
of 308,803 outputs
Outputs of similar age from Clinical and Translational Oncology
#15
of 19 outputs
Altmetric has tracked 23,001,641 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,318 research outputs from this source. They receive a mean Attention Score of 3.7. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 308,803 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.